August 28, 2025

Does Changing Biologics Clear Skin Faster?

The psoriasis treatment ladder may not apply to interclass biologic switching.

Conexiant

August 28, 2025

Girl With Waterdrop-Like Papules: What’s Your Diagnosis?

A teenager with atopic dermatitis presented with several painless, flesh-colored papules limited to the trunk. Dermoscopy and biopsy show selective loss of elastic fibers after prior molluscum contagiosum. What’s your diagnosis?

Conexiant

August 25, 2025

Baricitinib Aids Eyebrow, Eyelash Regrowth in Alopecia Areata

This study highlights baricitinib’s effectiveness in promoting eyebrow and eyelash regrowth in patients with alopecia areata across two phase III clinical trials.

Conexiant

August 25, 2025

Did Politics Delay CDC Measles Response?

Emails and interviews show CDC scientists were sidelined during the West Texas surge, leaving local officials without guidance as cases spread across the US and into Mexico.

KFF Health News

August 22, 2025

Nemolizumab Study Tracks 68 Weeks of Relief

A long-term clinical study finds that the biologic therapy nemolizumab, when used with topical corticosteroids, continues to improve itch, sleep, and skin symptoms in prurigo nodularis patients over 68 weeks.

Conexiant

August 14, 2025

Thai Trial Tests Turmeric Emulgel Skin Safety

Thai investigators test a botanical emulgel formulation to identify early safety signals related to skin irritation and allergenicity before advancing to patient trials.

Conexiant

August 04, 2025

Beta-HPV–Driven SCC Resolved After TCR Signaling Correction

Case study shows cutaneous squamous cell carcinoma linked to beta-human papillomavirus cleared following T-cell immune restoration.

Conexiant

April 19, 2024

Dosing Proceeds in GA Study

PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.

New Retinal Physician

April 17, 2023

Single-Agent Pembrolizumab May Benefit Patients With Advanced Desmoplastic Melanoma

Monotherapy with pembrolizumab led to clinical responses in 89% of patients with unresectable metastatic desmoplastic melanoma, according to results from the phase II S1512 clinical trial presented by...

The ASCO Post